Paper30128811
Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.
Klausner G and 9 others. Med Oncol, 2018. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. Papers, record 30128811. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30128811
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Anus Neoplasms | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Disease Management | Major topic |
| Radiotherapy, Intensity-Modulated | Major topic |
| Combined Modality Therapy | |
| Humans | |
| Neoplasm Staging |
Source PubMed
References93
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28258896 | The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. | Int J Radiat Oncol Biol Phys | 2017 | https://conductscience.org/library/papers/28258896 | PubMed |
| 2 | 25467588 | Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). | Lancet | 2015 | https://conductscience.org/library/papers/25467588 | PubMed |
| 3 | 25950188 | Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. | Cancer Invest | 2015 | https://conductscience.org/library/papers/25950188 | PubMed |
| 4 | 3920734 | Squamous cell carcinoma of the anal canal: treatment by external beam irradiation. | Radiother Oncol | 1985 | https://conductscience.org/library/papers/3920734 | PubMed |
| 5 | 3568920 | Epidermoid carcinoma of the anal canal. A series of 276 cases. | Dis Colon Rectum | 1987 | https://conductscience.org/library/papers/3568920 | PubMed |
| 6 | 8874455 | Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. | Lancet | 1996 | https://conductscience.org/library/papers/8874455 | PubMed |
| 7 | 23578724 | Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. | Lancet Oncol | 2013 | https://conductscience.org/library/papers/23578724 | PubMed |
| 8 | 6326995 | Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. | Cancer | 1984 | https://conductscience.org/library/papers/6326995 | PubMed |
| 9 | 27523411 | [Radiotherapy for anal canal cancers]. | Cancer Radiother | 2016 | https://conductscience.org/library/papers/27523411 | PubMed |
| 10 | 18430910 | Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. | JAMA | 2008 | https://conductscience.org/library/papers/18430910 | PubMed |
| 11 | 12555997 | Prognostic factors in anal carcinoma. | Pathology | 2002 | https://conductscience.org/library/papers/12555997 | PubMed |
| 12 | 22278906 | Definitive organ-sparing treatment of anal canal cancer: can we afford to question it? | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22278906 | PubMed |
| 13 | 18472366 | EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. | Int J Radiat Oncol Biol Phys | 2008 | https://conductscience.org/library/papers/18472366 | PubMed |
| 14 | 19203845 | Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. | Int J Radiat Oncol Biol Phys | 2009 | https://conductscience.org/library/papers/19203845 | PubMed |
| 15 | 19392867 | Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. | Aliment Pharmacol Ther | 2009 | https://conductscience.org/library/papers/19392867 | PubMed |
| 16 | 16607677 | Molecular biology of squamous cell carcinoma of the anus. | Br J Surg | 2006 | https://conductscience.org/library/papers/16607677 | PubMed |
| 17 | 22285668 | Setup variations in radiotherapy of anal cancer: advantages of target volume reduction using image-guided radiation treatment. | Int J Radiat Oncol Biol Phys | 2012 | https://conductscience.org/library/papers/22285668 | PubMed |
| 18 | 28972796 | PET imaging in anal canal cancer: a systematic review and meta-analysis. | Br J Radiol | 2017 | https://conductscience.org/library/papers/28972796 | PubMed |
| 19 | 26457030 | Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity. | World J Gastroenterol | 2015 | https://conductscience.org/library/papers/26457030 | PubMed |
| 20 | 11395235 | The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. | Int J Radiat Oncol Biol Phys | 2001 | https://conductscience.org/library/papers/11395235 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40120019 | Radiomics to predict tumor response to combination chemoradiotherapy in squamous cell carcinoma of the anal canal: a preliminary investigation. | Eur Radiol Exp | 2025 | https://conductscience.org/library/papers/40120019 | PubMed |
| 32842617 | Additional Value of 2-[18F]FDG PET/CT Comparing to MRI in Treatment Approach of Anal Cancer Patients. | J Clin Med | 2020 | https://conductscience.org/library/papers/32842617 | PubMed |
| 31574418 | Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). | Eur J Cancer | 2019 | https://conductscience.org/library/papers/31574418 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30128811
GET https://conductscience.org/api/papers/v1/30128811/references?page=2